With respect to the first and second generations of BCR-ABL tyrosine kinase protein inhibitors, PON was more successful in eliminating both BCR-ABL wild-type and mutant (BCR-ABLT315I) CML cells, thus reducing the possible evolution of resistance due to drug exclusion [2]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.